In a preclinical study, Zhao et al97 introduced a novel armed CEA-targeted CAR-T cell therapy that incorporates a SIRPγ-CD28 chimeric coreceptor, specifically designed to enhance the antitumor activity of CAR-T cells against CRC. Here, CD28 is linked to colorectal carcinoma.